Clinical Trials | September 23, 2025
Teva unveils promising SOLARIS resultsfor Olanzapine LAI
No post-injection Delirium/Sedation Syndrome (PDSS) observed through 56 weeks
No post-injection Delirium/Sedation Syndrome (PDSS) observed through 56 weeks
Tezspire nearly eliminated the need for surgery, reducing surgical intervention by 98 per cent
Pegozafermin offers a distinct mechanism of action with potential for enhanced efficacy and tolerability and opportunities for combination development with incretins
This predictive technology empowers people with diabetes to take preventive action before complications arise
The Phase Ib MAD study is a randomized, double-blind, placebo-controlled trial conducted in the United States
Merck opens first climate-neutral manufacturing facility in Ireland
The TULIP-SC trial investigated the efficacy and safety of subcutaneous Saphnelo
Wegovy achieved significant weight loss with one in three study participants losing 20% or more body weight
Subscribe To Our Newsletter & Stay Updated
